drugset
drugset / Trial / NCT04489940

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

NCT04489940 ↗

Phase 2 Terminated 11 enrolled EMD Serono Research & Development Institute, Inc. Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study was to evaluate bintrafusp alfa monotherapy in participants with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a centralized reverse transcriptase-polymerase chain reaction (RT-PCR) test.

Timeline

Start
2020-10-12
Primary completion
2022-01-27
Completion
2022-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bintrafusp alfa Protein / enzyme biologic 1200 mg Intravenous

Indications

triple-negative breast carcinoma